论文部分内容阅读
美国FDA已忠告医师及广大病人,关于修订西格列汀(sitagliptin)及西格列汀/二甲双胍处方,包括用该药后发生急性胰腺炎报告的信息。西格列汀为二肽酶-4(DPP-4)抑制剂,原批准用于配合控制饮食及运动,以控制成人2型糖尿
The FDA has advised physicians and the general public about the revisions to the sitagliptin and sitagliptin / metformin formulations, including the reports of acute pancreatitis following the drug. Sitagliptin is a dipeptidyl-4 (DPP-4) inhibitor originally approved for use in controlling diet and exercise to control type 2 diabetes in adults